Remibursement Limits, Antidepressants, and Outcomes
报销限额、抗抑郁药和结果
基本信息
- 批准号:7184353
- 负责人:
- 金额:$ 25.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAdverse effectsAntidepressive AgentsBritish ColumbiaCaringCost ControlCost SharingDatabasesDeductiblesDrug CostsDrug PrescriptionsDrug usageEducational workshopElderlyEnsureExpenditureHandHealthHealth systemHospitalizationIncomeInternationalInterviewMedicareMental DepressionOutcomeOutpatientsPatientsPharmaceutical PreparationsPoliciesPredispositionRegression AnalysisResourcesRiskSavingsSeriesSeveritiesSourceStable PopulationsStigmataSuicide attemptTimeTreatment ProtocolsUninsured Medical ExpenseVisitaccomplished suicidebasecopingcosteconomic outcomehealth care service utilizationnursing home length of stayolder patientpatient orientedprogramssocial stigma
项目摘要
DESCRIPTION (provided by applicant): Income-based deductibles (IBDs) for prescription drugs require elderly patients to pay all drug costs up to an amount determined by their incomes; this approach has been proposed for containing costs in a potential Medicare drug benefit program. Older patients taking antidepressants may be especially vulnerable to adverse effects from IBDs because of their limited resources, frequent need for multiple drugs, susceptibility to inappropriately taken regimens, and stigma associated with taking antidepressants. On the other hand, antidepressants are the single largest drug expenditure in many health systems. It is possible that IBDs may contain antidepressant costs without adverse effects, ensuring the fiscal viability of drug assistance programs. In July 2003, British Columbia residents equal to or >65 (N equal to approximately 520,000) will begin an IBD program, paying all drug costs up to 2-4% of their income out-of-pocket. We will use comprehensive drug and health care utilization databases and patient-centered information from interviews to evaluate this substantial coverage change in a large, stable population of elderly antidepressant users. Interrupted time-series regression analyses will identify the impact of IBDs on completed suicides and attempts, hospitalizations, emergency room care, nursing home stays, outpatient visits, antidepressant discontinuation, use of suboptimal regimens, overall net monetary savings, and out-of-pocket expenses for antidepressants. Elderly who discontinue or change to potentially suboptimal regimens are most likely to suffer adverse outcomes from IBDs, yet even severe effects in them may be missed in overall analyses. We will focus on high-risk patients who discontinue or change regimens to see if IBDs negatively impact health, utilization, or economic outcomes. Using patient-centered information captured in interviews, we will identify the burdens and coping strategies elderly use to deal with greater antidepressant cost-sharing, such as reducing drug use, obtaining nontraditional sources of drugs, or doing without necessities. We will examine whether depression severity and other burdens are greater during annual periods when patients are fully responsible for paying vs. fully reimbursed for their drugs. We will conduct extensive dissemination activities, including convening an international workshop on drug cost containment policies among elderly users of psychiatric medications. We will also use other national and international forums to inform ongoing debates over drug coverage for vulnerable elderly patients with depression.
描述(由申请人提供):处方药的基于收入的免赔额(IBD)要求老年患者支付所有药物费用,最高金额由其收入决定;这种方法已被提议用于控制潜在医疗保险药物福利计划中的费用。服用抗抑郁药的老年患者可能特别容易受到IBD的不良反应的影响,因为他们的资源有限,经常需要多种药物,对不适当服用的方案敏感,以及与服用抗抑郁药相关的耻辱。另一方面,抗抑郁药是许多卫生系统中最大的单一药物支出。IBD可能包含抗抑郁药成本而不会产生不良影响,从而确保药物援助计划的财政可行性。2003年7月,不列颠哥伦比亚省65岁或65岁以上的居民(N约等于520,000)将开始IBD计划,自费支付所有药物费用,最高可达其收入的2-4%。我们将使用全面的药物和医疗保健利用数据库和以患者为中心的信息,从访谈中评估这一重大覆盖面的变化,在一个大的,稳定的老年抗抑郁药使用者的人口。 中断的时间序列回归分析将确定IBD对自杀和自杀未遂、住院、急诊室护理、疗养院住宿、门诊就诊、抗抑郁药停药、使用次优方案、总体净货币储蓄和抗抑郁药自付费用的影响。 停止或改变为潜在次优方案的老年人最有可能遭受IBD的不良后果,但即使是严重的影响也可能在总体分析中遗漏。我们将重点关注停止或改变治疗方案的高风险患者,以了解IBD是否会对健康,利用或经济结果产生负面影响。 使用以患者为中心的信息,在采访中,我们将确定老年人使用的负担和应对策略,以处理更大的抗抑郁药的成本分担,如减少药物使用,获得非传统的药物来源,或没有必需品。我们将研究抑郁症的严重程度和其他负担是否在患者完全负责支付与完全报销药物的年度期间更大。 我们将开展广泛的宣传活动,包括在使用精神药物的老年人中举办一次关于控制药物费用政策的国际讲习班。我们还将利用其他国家和国际论坛,为正在进行的关于弱势老年抑郁症患者药物覆盖范围的辩论提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sebastian G. Schneeweiss其他文献
Sebastian G. Schneeweiss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sebastian G. Schneeweiss', 18)}}的其他基金
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations
在临床实践和代表性不足的人群中对特应性皮炎的新型全身治疗进行安全监测的新方法
- 批准号:
10339592 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations
在临床实践和代表性不足的人群中对特应性皮炎的新型全身治疗进行安全监测的新方法
- 批准号:
10559698 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)
使用前瞻性纵向保险索赔重复的随机心血管试验:应用流行病学技术(RCT DUPLICATE)
- 批准号:
10606588 - 财政年份:2019
- 资助金额:
$ 25.84万 - 项目类别:
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)
使用前瞻性纵向保险索赔重复的随机心血管试验:应用流行病学技术(RCT DUPLICATE)
- 批准号:
9898456 - 财政年份:2019
- 资助金额:
$ 25.84万 - 项目类别:
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)
使用前瞻性纵向保险索赔重复的随机心血管试验:应用流行病学技术(RCT DUPLICATE)
- 批准号:
10392863 - 财政年份:2019
- 资助金额:
$ 25.84万 - 项目类别:
Assessment of Treatment Effects in High-Dimensional, Routine Care Claims Data
高维常规护理索赔数据中的治疗效果评估
- 批准号:
8037863 - 财政年份:2010
- 资助金额:
$ 25.84万 - 项目类别:
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects
分析复杂的医疗数据以确定观察到的药物作用的因果关系
- 批准号:
8143550 - 财政年份:2009
- 资助金额:
$ 25.84万 - 项目类别:
Antidepressant Use and Suicidality: Comparative Safety in Children and Adults
抗抑郁药的使用和自杀:儿童和成人的相对安全性
- 批准号:
7929307 - 财政年份:2009
- 资助金额:
$ 25.84万 - 项目类别:
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects
分析复杂的医疗数据以确定观察到的药物作用的因果关系
- 批准号:
7940855 - 财政年份:2009
- 资助金额:
$ 25.84万 - 项目类别:
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug Effects
分析复杂的医疗数据以确定观察到的药物作用的因果关系
- 批准号:
7767483 - 财政年份:2009
- 资助金额:
$ 25.84万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 25.84万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 25.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 25.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 25.84万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 25.84万 - 项目类别:
Studentship